Obesity Medicine

ObesityWeek 2022: Regardless of the number of obesity-related comorbidities, tirzepatide was associated with a greater reduction in body weight than placebo.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

ObesityWeek 2022: Tirzepatide-induced weight reduction was associated with body composition improvements in adults with obesity/overweight, found analysis of SURMOUNT-1.

Adults with obesity who have an inadequate response to lifestyle interventions alone should be offered 1 of 4 suggested medications.

The first-in-class dual incretin receptor agonist was granted fast track designation for investigation in adults with obesity or overweight with weight-related comorbidities.

Children with obesity enrolled in the FitTastic study group had more favorable BMI patterns compared to control group, according to longitudinal effectiveness study.

Adolescents with severe obesity who underwent bariatric surgery before age 22 lost 31.1% body weight and kept it off over a decade later, showed new study.

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Educating patients with obesity about the link between poor sleep and weight gain is crucial. Review 5 key elements for achieving better sleep, here.

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

A free, automated online behavioral weight loss program led to a mean 5% reduction in weight over 12 weeks without clinician involvement, a new study reports.

Excess weight diminishes the development and function of the musculoskeletal system at any point in the lifespan. An obesity specialist highlights the dangers.

With the iDip program, 50% of adults reached the researchers' goal of losing at least 5% body weight and maintained it for 1 year without strict dieting.

Social determinants of health, including education and income level and race/ethnicity, are drivers of declining cardiometabolic health in the US, says investigator Meghan O'Hearn.

Americans sitting on the cusp of cardiometabolic disease, ie, with prediabetes, prehypertension, overweight but not obesity, need intervention, now.

US prevalence of optimal cardiometabolic health has declined as poor levels have risen significantly over 2 decades. Investigator Meghan O'Hearn, MS, details the research.

Insurance companies believe the required presurgical programs reduce complications and improve outcomes but a new study strongly suggests the opposite.

ENDO 2022: Findings from the long-term, real-world study of meds for maintenance of meaningful weight loss support wider uptake of the agents, authors say.

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

Understanding the interplay between obesity and depression in children is key for clinicians to best advise this patient population. An overview, here.

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.

Women, Black individuals, and adults diagnosed with overweight or obesity in more recent years were more likely to receive a referral, according to new study.

The proportion of overweight, obesity, or severe obesity increased from 38% to 45% among 4500 young people seen in a primary care network where most receive public insurance.